Investigation of Insulin Receptor Substrate-1 and the Prevalence of Type 2 Diabetes Mellitus among Hepatitis C Infected Patients
DOI:
https://doi.org/10.46966/msjar.v5i2.183Keywords:
Hepatitis C virus, Diabetes Mellites, Insulin Receptor Substrate-1Abstract
Background: The hepatitis C virus causes a lot of deaths and illnesses across the world. It accounts more than 20% of hepatocellular carcinoma and chronic liver disease patients. In addition to causing liver illness, hepatitis C virus infection may produce extrahepatic symptoms, such as autoimmune diseases. Type 2 diabetes is more common in these individuals. There is strong evidence to support this theory, since research has shown that hepatitis C virus (HCV) infected individuals are more likely to develop type 2 diabetic mellitus (DM). Aim of the study: Estimation level of insulin receptor substrate-1 and prevalence DM in HCV patient. Material and Methods: It is a case-control study that was held in Najaf governorate between July 2023 and December 2023 with a sample size of 128 subjects. The subject group included 128 (41 males and 23 females) HCV-infected patients, and the control group attended the specialized center for gastroenterology and hepatology and the public health laboratory. Their ages ranged from 26 to 70 years. Used ELISA Tanique for estimation of IRS-1, HCV IgG, and HbA1c and estimation of AST, ALT, and ALP in a spectrophotometer. The SPSS software package for Windows, version 27 (Build 27.0.1.0, copyright © IBM Corp., 2022, USA), was used to analyse the data. Conclusion: The hepatitis C virus leads to the destruction of IRS-1 in different ways and causes insulin resistance and type 2 diabetes mellitus.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Mohammed Ghali Aklo, Dhefaf Hameed AL_Mudhafar
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
